June 24, 2014
by PharmaReviews
0 comments
Bayer has linked up with Dimension Therapeutics to develop a gene therapy for haemophilia A in a deal that could be worth about $250 million to the US biotech. The German group has long been a major player in haemophilia … Continue reading
June 24, 2014
by PharmaReviews
0 comments
Roche has hooked up with healthcare venture capitalist group Versant and research group Inception Sciences to create a new biotechnology company focused on developing treatments for multiple sclerosis. Crowned Inception 5, the newcomer will dedicate itself to designing novel … Continue reading
June 14, 2014
by PharmaReviews
0 comments
Pharmaceutical Review (www.pharmareview.wordpress.com); Pakistan Pharmacist Association (PPA) Baluchistan is on strike and arranged a protest camp at Press Club, Quetta Baluchistan regarding provincial service structure . They are demanding the internationally recognized and WHO recommended service structure to provide the … Continue reading
June 14, 2014 by PharmaReviews | 0 comments
June 12, 2014
by PharmaReviews
0 comments
The U.S. Food and Drug Administration today approved Eloctate, Antihemophilic Factor (Recombinant), Fc fusion protein, for use in adults and children who have Hemophilia A. Eloctate is the first Hemophilia A treatment designed to require less frequent injections when used … Continue reading
June 12, 2014
by PharmaReviews
0 comments
McMaster University researchers may have found a novel way to suppress the devastating side effect of statins, one of the worlds’ most widely used drugs to lower cholesterol and prevent heart disease. The research team – led by Jonathan Schertzer, … Continue reading
June 9, 2014
by PharmaReviews
1 Comment
GlaxoSmithKline has begun a Phase III study cardiovascular outcomes study of its investigational compound losmapimod in patients with acute coronary syndrome. The trial will assess whether losmapimod can reduce the risk of a subsequent cardiac event when administered orally twice … Continue reading
June 9, 2014
by PharmaReviews
0 comments
Pfizer has entered a five year collaborative agreement with the Global Medical Excellence Cluster (GMEC) in the UK that will conduct research and develop new medicines aimed at rare diseases. GMEC is comprised of six British universities: Cambridge University, Imperial College … Continue reading
June 7, 2014 by PharmaReviews | 0 comments
June 4, 2014 by PharmaReviews | 0 comments
